Intestinal Lesions of Streptozotocin Diabetes and the Effects of Azadirachta indica Treatment

Authors

  • Oluwole B Akinola
  • Ezekeil A Caxton Martins
  • Ahelaje A Abdulazeez
  • Luciana Dini

Abstract

Objective: Streptozotocin (STZ) uptake into cells is mediated by GLUT-2 transporter. Besides pancreatic B cells, this transporter is also expressed by epitheliocytes of the intestinal mucosa, hepatocytes, and cells of renal tubules. In this work, we studied the effects of chronic streptozotocin diabetes on the morphology of ileal epithelium. We also report the effects of chronic Azadirachta indica treatment on STZ-induced ileal lesions.

Material Methods: Twenty-five Wistar rats of both sexes (5-8 weeks old) were used. Diabetes was induced in 15 rats with an i.p. dose of 70 mg/kg bw/d of STZ in citrate buffer (0.1 M; pH 4.5). Animals were randomly sorted into five groups of five rats each: control, diabetic, diabetic + neem, diabetic + glibenclamide, neem only.

Results: Azadirachta indica was administered at 500 mg/kg bw/d for 50d. By 50d, diabetic rats showed superficial erosion of ileal mucosa with necrosis of goblet cells. Such lesions were however absent in hyperglycemic and normoglycemic rats treated with neem.

Conclusion: These findings suggest that (i) chronic streptozotocin diabetes is associated with intestinal lesions; (ii) neem prevents STZ-induced intestinal lesions; and (iii) exposure of intestinal mucosa to the leaf extract of Azadirachta indica in non-diabetic rats is not associated with deleterious effects.

Key words: Azadirachta indica, streptozotocin diabetes, intestinal lesions

Downloads

Published

03-08-2016

How to Cite

1.
Akinola OB, Martins EAC, Abdulazeez AA, Dini L. Intestinal Lesions of Streptozotocin Diabetes and the Effects of Azadirachta indica Treatment. Pak J Pathol [Internet]. 2016 Aug. 3 [cited 2024 Mar. 28];20(2). Available from: https://pakjpath.com/index.php/Pak-J-Pathol/article/view/256

Issue

Section

Articles